Navigation Links
PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Date:8/20/2007

Novel cardioprotective agent to move forward in Phase III development

NEW YORK, Aug. 20 /PRNewswire/ -- PeriCor Therapeutics announced today that its licensing agreement for acadesine with Schering-Plough Corporation has become effective. The agreement grants Schering-Plough exclusive worldwide rights for the development and commercialization of PeriCor's lead compound, acadesine. Financial terms of the transaction were not disclosed.

Acadesine is currently under evaluation in Phase III clinical development as an intravenous infusion for the prevention of adverse cardiovascular and cerebrovascular outcomes that occur as complications associated with ischemia-reperfusion injury in patients undergoing coronary artery bypass graft (CABG) surgery. Acadesine has been studied in placebo-controlled trials that enrolled more than 4,000 patients. Schering-Plough will conduct an additional randomized, placebo-controlled Phase III trial needed for regulatory approval. An agent, such as acadesine, that can be shown to reduce the surgical complications of stroke, heart failure and death that can accompany CABG would not only make an important contribution to patients' well-being, but would also be anticipated to reduce health care costs dramatically.

"Schering-Plough possesses the vital organizational and financial resources to complete the clinical and regulatory processes required to make this life-saving medicine available to cardiac surgeons and anesthesiologists around the world," said Richard R. Stover, President and Chief Executive Officer of PeriCor Therapeutics. Commenting further, Mr. Stover said, "We are especially impressed with the caliber of Schering-Plough's cardiovascular group in clinical development, medical, and marketing activities and their unparalleled record of innovation in this therapeutic area."

Previous clinical experience with acadesine in placebo-controlled studies in CABG surgery suggests that acadesine may have unique
'/>"/>

SOURCE PeriCor Therapeutics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Speaker announces business members of IT Task Force
3. Doyle announces technology tax credits for Berbee
4. Doyle announces new energy, global warming policies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , 25 novembre 2014 Theravalues Corporation est ... le marché européen au salon Hi Europe 2014 ... ). Curcumine la plus biodisponible ... amorphe (non-cristalline) à des ingrédients approuvés par les ... pigment jaune présent dans la racine de curcuma ...
(Date:11/26/2014)... 25 novembre 2014 /PRNewswrie/ -- Theravalues Corporation annuncia con ... europeo in occasione di Hi Europe 2014 (dal 2 ... Si tratta della curcumina con la maggiore biodisponibilità ... cristalli) e ingredienti approvati dalle norme europee. ... della pianta curcumina ( Curcuma longa ) che è ...
(Date:11/24/2014)...  IGI Laboratories, Inc. (NYSE MKT: IG), a ... company, today announced it has submitted an additional abbreviated ... Drug Administration (FDA), which brings the Company,s total number ... submissions now pending at the FDA. ... Company, commented, "Our team here at IGI has continued ...
(Date:11/24/2014)...  Last week, Representatives Gus Bilirakis ... a bold bipartisan step on behalf of patients ... Original co-sponsors of the legislation include Representatives McCaul ... drug makers and innovators to "repurpose" major market ... which opens the door to the development of ...
Breaking Biology Technology:La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... With the advent of liquid chromatography/ mass spectrometry and information dependent ... characterise metabolites while to quantifying their parents during metabolic stability studies. ... Abstract , ... based on a triple quadrupole ion path and is capable of ...
... Characterization of nucleotide and nucleoside analogs from Taraxacum mongolicum, ... time using liquid chromatography tandem mass spectrometry (LC/MS/MS). The ... and nucleoside standards with product and precursor scans of ... be major active ingredients which have anti-Herpes simplex virus ...
... , ... Edman sequence analysis and electrospray tandem mass spectrometry provides accurate and detailed structural ... Purpose , ... peptides is greatly facilitated using a combination of the Procise cLC 492 sequencing ...
Cached Biology Technology:Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS 2Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS 3Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS 4Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS 5Isolation and Characterization of Anti-Viral Nucleoside Compounds from the Chinese Herb Taraxacum Mongolicum 2Isolation and Characterization of Anti-Viral Nucleoside Compounds from the Chinese Herb Taraxacum Mongolicum 3Efficient Primary Structure Elucidation of Disulfide-bridged Peptides 2Efficient Primary Structure Elucidation of Disulfide-bridged Peptides 3Efficient Primary Structure Elucidation of Disulfide-bridged Peptides 4Efficient Primary Structure Elucidation of Disulfide-bridged Peptides 5
(Date:11/21/2014)... Strict laws against distracted driving and the ... American and European automotive sector towards gesture recognition technologies. ... that are intuitive and able to retrieve information with ... New analysis from Frost & Sullivan,s Strategic ... Europe and North America ...
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
(Date:11/12/2014)... Fla. , Nov. 12, 2014 Crossmatch™, ... today that its U.are.U ® fingerprint readers have ... chain in Central Mexico . The ... 2014 to eliminate payroll issues caused by employees clocking ... installing the U.are.U fingerprint readers, Montparnasse relied on paper ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... CHAMPAIGN, Ill. By creating a model of the active ... University of Illinois have described a catalyst that acts like ... work in a paper accepted for publication in the ... the journal,s Web site. , Scientists have long been puzzled ...
... to 500 million cases of malaria are diagnosed each ... prevent and treat malaria do exist, the demand for ... malaria parasites have developed a resistance to existing medications. ... of Medicine have discovered one way to stop malaria ...
... considered the one and only way biological traits could ... Not anymore. Increasingly, biologists are finding that non-genetic ... sometimes be passed on to offspringa phenomenon known as ... of The Quarterly Review of Biology lists ...
Cached Biology News:New lead on malaria treatment 2100 reasons to change the way we think about genetics 2100 reasons to change the way we think about genetics 3
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
...
... PI is used in conjuction with ... in the earlier stages of apoptosis (Annexin ... are in later stages of apoptosis or ... PI is detected in the orange range ...
... were cultured in RPMI 1640 with 2 mM ... growth. In order to keep the antigens ... acetone-methanol. The cells are arrayed on a ... wells surface specifically treated to enhance cellular attachment ...
Biology Products: